Jervis P, Sosa-Eroza E

Language: Spanish
References: 8
Page: 56-57
PDF size: 47.09 Kb.

Text Extraction

No abstract

REFERENCES

1. Márquez-López JA, Mendoza-Zubieta V, Ramírez-Rentería C, Mercado M. Características clínicas, bioquímicas y radiológicas de los prolactinomas resistentes a cabergolina en el Hospital de Especialidades del CMN Siglo XXI. Rev Endocr Nutr 2011; 19: 69-73.

2. Delgrange E, Daems T, Verhelst J, Abs R, Maiter D. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol 2009; 160: 747–752.

3. Guillan MP, Molitch ME, Lombardi G, Colao A. Advance in the treatment of prolactinomas. Endocr Rev 2006; 27: 485-534.

4. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM et al. Diagnosis and treatment of hyperprolactinemia: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2011; 96: 273-288.

5. Molitch ME. Pharmacologic resistance in prolactinoma patients. Pituitary 2005; 8: 43-52.

6. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999; 84: 2518-2522.

7. Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, Kubo O, Hori T, Takano K. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab 2008; 93: 4721-4727.

8. Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 2000; 85: 2247-2252.